





RealRate

# PHARMACEUTICAL 2021

AgeX Therapeutics Inc.  
Rank 372 of 402



The relative strengths and weaknesses of AgeX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AgeX Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 36% points. The greatest weakness of AgeX Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 238% points.

The company's Economic Capital Ratio, given in the ranking table, is -305%, being 353% points below the market average of 47%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 2,283             |
| Cost of Goods Sold                          | 158               |
| Intangible Assets                           | 1,592             |
| Liabilities, Current                        | 5,357             |
| Liabilities, Non-Current                    | 64                |
| Other Assets                                | 50                |
| Other Compr. Net Income                     | 74                |
| Other Expenses                              | -150              |
| Other Liabilities                           | 3,900             |
| Other Net Income                            | -455              |
| Other Revenues                              | 1,868             |
| Property and Equipment                      | 0                 |
| Research and Development                    | 4,978             |
| Selling, General and Administrative Expense | 7,403             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 3,925             |
| Liabilities              | 9,321             |
| Expenses                 | 12,389            |
| Revenues                 | 1,868             |
| Stockholders Equity      | -5,396            |
| Net Income               | -10,976           |
| Comprehensive Net Income | -10,939           |
| Economic Capital Ratio   | -305%             |